혈액종양내과김범준 교수 사진

김범준

진료과 : 혈액종양내과 홈페이지

전문진료분야 : 혈액종양내과 (혈액질환 및 고형암)

학력 및 경력

내용 숨기기
학력
한림대학교 의과대학 졸업 (2010)
한림대학교 대학원 의학박사 (2020)

경력
한림대학교성심병원 내과 전공의 수료 (2015)
서울아산병원 종양내과 임상강사 (2016)
한림대학교강남성심병원 혈액종양내과 임상강사 (2017)
국군수도병원 혈액종양내과 과장 (2018-2020)
現한림대학교성심병원 혈액종양내과 조교수

수상경력

내용 숨기기
1. 올해의 연구자 표창 (2017, 국군수도병원)

2. 한림학술상, 최우수상 (2018, 한림대학교 의과대학 동문회)

국내학회지 발표논문

내용 숨기기
1. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Research and Treatment 2017

2. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. British Journal of Cancer 2017

3. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. Cancer Research and Treatment 2017

4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemotherapy and Pharmacology 2017

5. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Journal of Cancer 2017

6. Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. Indian Journal of Hematology and Blood Transfusion 2017

7. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. Oncotarget 2017

8. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget 2017

9. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice 2018

10. Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. Cancer Research and Treatment 2019